ABOUT US | PEOPLE AT CIRA | RESEARCH | NEWS | PUBLICATIONS | EVENTS | OPPORTUNITIES

FOR OUR AFFILIATES
PEOPLE AT CIRA
Brief Bio | Areas of Expertise | Affiliated Projects | Publications | Courses

Gerald H. Friedland, M.D.
blue arrow Professor, Internal Medicine
blue arrow Professor, Epidemiology & Public Health
blue arrow Investigator, Clinical and Health Services Research (CHSR) Core

Contact:
blue arrow gerald.friedland@yale.edu
blue arrow Ph: (203) 688-6959
 Gerald H. Friedland


Brief Bio:
Dr. Friedland is the Director of the AIDS Program at Yale New Haven Hospital and Professor of Medicine and Epidemiology and Public Health at Yale School of Medicine. He is a former member of the Governing Council of the International AIDS Society, National Advisory Council, National Institute on Drug Abuse and Advisory Council, Office of AIDS Research, and currently serves on the WHO HIV/TB Working Group and as the Chairman of the Board of Directors of the Aaron Diamond AIDS Research Center in New York City.

Dr Friedland has been directly involved in the development of comprehensive HIV care programs since the beginning of the HIV epidemic in 1981. His work was initially in the Bronx, New York and since 1991, in New Haven, Connecticut. He has developed and directed large-scale clinical and epidemiologic studies among vulnerable populations with and at risk for HIV disease. His group presented the first convincing evidence of lack of transmission of HIV by close personal contact, defined the predictors of HIV transmission and natural history of HIV disease among injection drug users and the risk of reactivation of tuberculosis among those co-infected with M.Tb and HIV. More recently, Dr. Friedland has worked on clinical trials of antiretroviral therapies. He is currently the Principal Investigator of New England ProACT, a regional AIDS clinical trials network affiliated with the CPCRA/INSIGHT, an NIH supported multisite program specializing in large-scale antiretroviral therapy strategy trials. In this work he has focused on the recruitment, enrollment, retention and special issues of HIV therapeutics among injection drug users and other marginalized populations, including pioneering work in defining phamacokinetic drug interactions between HIV and substance abuse therapies.

Dr. Friedland’s research also has focused on studies at the interface of biology, clinical care and behavior, including adherence to HIV therapies and the integration of prevention strategies and clinical care, notably in the development and testing of interventions to reduce HIV transmission risk among HIV+ persons in clinical care.

Dr. Friedland is also actively involved in HIV/AIDS international research aimed at providing access to antiretroviral therapy in resource limited settings. The major focus of this work is the integration of HIV and TB care and treatment in co-infected patients with the aim of improving diagnosis, treatment and outcome of both diseases. This work has led to the discovery of extensively resistant tuberculosis (XDR TB) as a major cause of death among HIV/TB co-infected patients in South Africa and now focuses on the diagnosis, treatment and reduction of transmission of multiple drug resistant (MDR) and XDR TB in HIV co-infected patients. Dr. Friedland directs and participates in several research projects addressing these issues in rural and urban South Africa, supported by charitable research foundations and the NIH. He is a Visiting Professor at the Nelson. R Mandela School of Medicine of the University of KwaZulu Natal in Durban, South Africa and the Mailman School of Public Health of Columbia University.

Areas of Expertise:
HIV/AIDS,Infectious Diseases,Tuberculosis

CIRA Affiliated Projects:
Direct/Observed Therapy/Community-Released HIV+Prisoners
Funder:
National Institute on Drug Abuse
Status: Active
Region:
U.S. - Connecticut
Opioids & HIV Medications: Interactions in Drug Abusers
Funder:
National Institute on Drug Abuse
Status: Active
Region:
U.S. - Connecticut, U.S. - Outside of CT.
Combating MDR and SDR TB and HIV in Rural South Africa
Funder:
Doris Duke Foundation
Status: Completed
Region:
Africa - South Africa
Expansion and Integration of TB/HIV Care and Treatment in Rural KwaZulu Natal, South Africa
Funder:
President's Emergency Program for AIDS Relief (PEPFAR)
Status: Completed
Region:
Africa - South Africa
Increasing Drug Users' Adherence to HIV Therapeutics
Funder:
National Institute on Drug Abuse
Status: Completed
Region:
U.S. - Connecticut
Modeling HIV Subjects' Electronic Monitoring Data
Funder:
National Institute of Allergy and Infectious Disease
Status: Completed
Region:
U.S. - Connecticut, U.S. - Outside of CT.
Provision of HIV Care and Antiretroviral Therapy Through a Strengthened Community-Based Tuberculosis Directly Observed Therapy Program in Rural South Africa: The Sizon’qoba ("We Shall Overcome") Project
Funder:
Doris Duke Foundation
Status: Completed
Region:
Africa - South Africa
Secure the Future Monitoring and Evaluation Unit
Funder:
Bristol-Myers Squibb Foundation
Status: Completed
Region:
Africa - Central and Western, Africa - Other, Africa - South Africa
Training in HIV Prevention & Care Research in South Africa-ICOHRTA
Funder:
Fogarty International Center/National Institute on Drug Abuse
Status: Completed
Region:
Africa - South Africa

Selected Publications:
2009

Shenoi, S., Heysell, S., Moll, A., Friedland, G.  (2009). Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion in Infectious Diseases, 22(1), 11-17.

Gandhi, N., Moll, A., Lalloo, U., Pawinski, R., Zeller, K., Moodley, P., Meyer, E., Friedland, G.  (2009). Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: the Sizonq’oba Study. Journal of Acquired Immune Deficiency Syndromes, 50(1), 37-43.

2008

Mannheimer, S., Thackeray, L., Huppler-Hullsidk, K., Chesney, M., Gardner, E., Wu, A., Telzak, E., Lawrence, J., Friedland, G.  (2008). A Randomized Comparison of Two Instruments for Measuring Self-Reported Antiretroviral Adherence. AIDS Care, 20(2), 161-169.

Bruce, R.D., Altice, F.L., Friedland, G.  (2008). A Review of Pharmacokinetic Drug Interactions Between Drugs of Abuse and Antiretroviral Medications: Implications and Management for Clinical Practice. Expert Review of Clinical Pharmacology, 1(1), 115-127.

Norton, W.E., Amico, K.R., Fisher, W.A., Copenhaver, M.M., Kozal, M.J., Cornman, D.H., Friedland, G., Fisher, J.D.  (2008). Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care, 20(4), 462-9.

Mosam, A., Hurchkand, H.P., Cassol, E., Page, T., Casso, S., Bodasing, U., Aboobaker, J., Dawood, H., Friedland, G.H.  (2008). Characteristics of HIV-1-Associated Kaposi's sarcoma Among Women and Men in South Africa. International Journal of STD & AIDS, 19(6), 400-405.

Cornman, D., Kiene, S., Christie, S., Fisher, W., Shuper, P., Pillay, S., Friedland, G., Thomas, C., Lodge, L., Fisher, J.  (2008). Clinic-based Intervention Reduces Unprotected Sexual Behavior Among HIV-Infected Patients in KwaZulu-Natal, South Africa: Results of a Pilot Study. Journal of Acquired Immune Deficiency Syndromes, 48(15), 553-560.

Padayachi, N., Friedland, G.  (2008). Decentralised Management of Drug-Resistant Tuberculosis (MDR and XDR TB) in South Africa: An Alternate Model of Care. International Journal of Tuberculosis and Lung Disease, 12(8), 978-980.

Gardner, E.M., Sharma, S., Peng, G., Huppler-Hulsiek, K., Burman, W.J., MacArthur, R.D., Chesney, M., Telzak, E., Friedland, G.  (2008). Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS, 22(1), 75-82.

Burman, W., Grund, B., Neuhaus, J., Douglas Fr., J, Friedland, G., Telzak, E., Colebunders, R., Paton, N., Fisher, M., Rietmeijer, C.  (2008). Episodic Antiretroviral Therapy Increases HIV Transmission risk Compared With Continuous Therapy: Results of a Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes, 49(2), 142-150.

Andrew, J., Gandhi, N., ,Moodley, P., Shah, S., Bohlken, L., Moll Pillay, M., Friedland, G., Sturm, W.  (2008). Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa. Journal of Infectious Diseases, 198(11), 1582-9.

Mannheimer, S., Matts, J., Gardner, E., Telzak, E., Child, C., Wu, A., Chesney, M., Friedland, G.  (2008). Mild-to Moderate Symptoms Worsen Quality of Life in HIV-Infected Individual. Clinical Infectious Diseases, 46(6), 941-45.

Friedland, G.  (2008). Protecting Health Care Workers; The Critical Role of Airborne Infection Control. International Journal of Tuberculosis and Lung Disease, 12(6), 585.

Burman, W., Grund, B., Roediger, M., Friedland, G., Darbyshire, J., Weu, A.  (2008). The Impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life. Journal of Acquired Immune Deficiency Syndromes, 47(2), 185-193.

2007

Springer, A.D., Friedland, G.H., Doros, G., Pesanti, E., Altice, F.L.  (2007). Antiretroviral Treatment Regimen outcomes Among HIV-Infected Prisoners. HIV Clinical Trials, 8(4), 205-212.

Friedland, G., Harries, A., and Coetzee, D.  (2007). Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. Journal of Infectious Diseases, 196(Suppl 1), S114-S123.

McCance-Katz, E.F., Moody, D.E., Morse, G., Quing Ma, Q., DiFrancesco, R., Friedland, G.  (2007). Interactions between Buprenorphine and Atazanavir or Atazanavir/Ritonavir. Drug and Alcohol Dependence, 91(2-3), 269-278.

Padayatchi, N., Friedland, G.  (2007). Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opinion Pharmacotherapy, 8(8), 1035-37.

Andrews, J., Shah, N.S., Ghandi, N., Moll, A.,Friedland, G.  (2007). Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Roll-Out in South Africa. Journal of Infectious Diseases, 45(6), 770-8.

Basu, S., Andrews, J., Poolman, E., Ghandi, N., Shah, S. Moll, A. Moodley, P., Galvani, A., Friedland, G.  (2007). Prevention of Nosocomial Transmission of Extensively Drug-resistant Tuberculosis in Rural South African Hospitals: A Epidemiological Modelling Study. Lancet, 370(9597), 1500-1507.

Altice, F.L., Smith-Rohrberg, Maru D., Bruce, R.D., Springer, S.A., and Friedland, G.H.  (2007). Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases, 45(6), 770-778.

Tsiouris, S, Ghandi, N., El-Sadr, W., Friedland, G.  (2007, ). Tuberculosis and HIV - Needed: A New Paradigm for the Control and Management of Linked Epidemics. eJIAS, pp. 62.

Friedland, G.H.  (2007). Tuberculosis, Drug Resistance, and HIV/AIDS: A Triple Threat. Current Infectiouse Disease Reports, 9(3), 252-261.

2006

Bruce, R.D., Altice, F.L., Gourevitch, M.N., and Friedland, G.H.  (2006). Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications: Implications and Management for Clinical Practice. Journal of Acquired Immune Deficiency Syndromes, 41(5), 563-572.

2004

Altice, F.L., Mezger, J., Hodges, J., Bruce, R.D., Marinovich, A., Walton, M., Springer, S.A., and Friedland, G.  (2004). Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases, 38(Suppl 5), S376-387.

2003

Altice, F.L., Springer, S., Buitrago, M., Hunt, D.P. and Friedland, G.H.  (2003). Pilot Study to Enhance HIV Care Using Needle Exchange-based Health Services for Out-of-treatment Injecting Drug Users. Journal of Urban Health, 80(3), 416-27.

2002

Broadhead, R.S., Heckathorn, D.D., Altice, F.L., van Hulst, Y., Carbone, M., Friedland, G.H., O'Connor, P.G. and Selwyn, P.A.  (2002). Increasing Drug Users' Adherence to HIV Treatment: Results of a Peer-Driven Intervention Feasibility Study. Social Science and Medicine, 55(2), 235-46.

2001

Altice, F.L., Mostashari, F. and Friedland, G.H.  (2001). Trust and the Acceptance of and Adherence to Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes, 28(1), 47-58.

1998

Altice, F.L. and Friedland, G.H.  (1998). The Era of Adherence to HIV Therapy. Annals of Internal Medicine, 129(6), 503-5.

CIRA eBULLETIN
Sign up to receive CIRA's weekly eBulletin.

YACS@CIRA
Thursday, 12/03
12:30 PM - 1:30 PM

Speaker: Nabila El-Bassel, Columbia University

Title: HIV Among Drug Users in Kazakhstan: Driving Forces and Implications for HIV Prevention & Treatment

Location: CHIP, 2006 Hillside Rd Unit 1248, Storrs, CT

Video Conference: CIRA, Ste. 200, Rm. 202, 135 College St, New Haven, CT
RSVP
CIRA NOW ON YouTube
YACS@CIRA featuring Daliah Heller from the NYC Department of Health & Mental Hygiene is now on YouTube. Check it out.
YouTube